Published 1 day ago • loading... • Updated 8 hours ago

Novo Nordisk shares fall 5.5% after latest trial results for its next-generation weight loss drug

Summary

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop 15.7% of their weight after 68 weeks.

24 Articles

All

Left

Center

Right

Seeking Alpha

Viking, other obesity players fall following Novo Nordisk CagriSema results

Pharma stocks focused on weight loss dip as data on Novo Nordisk's obesity drug CagriSema disappoints. Read more here.

10 hours ago·United States

Read Full Article

Fox Business

Novo Nordisk shares fall on weight-loss drug trial

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

11 hours ago·United States

Read Full Article

STAT

Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial

Shares of Novo Nordisk dropped Monday after the company reported that its next-generation obesity drug produced weight loss results in diabetes patients that fell short of investors’ expectations, the second major data release that financial observers were disappointed by. In a late-stage trial of people with obesity and type 2 diabetes, the treatment, called CagriSema, led patients to lose 13.7% of their weight over 68 weeks when looking at all…

12 hours ago·Boston, United States

Read Full Article

Reuters

Novo Nordisk trial with next-gen diabetes drug shows 15.7% weight loss but shares fall

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks, but shares fell, likely on the lower-than-expected weight loss.

15 hours ago·United Kingdom

Read Full Article